These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18566486)

  • 1. A Markov model simulation of the impact of treatment persistence in postmenopausal osteoporosis.
    Cotté FE; Fautrel B; De Pouvourville G
    Med Decis Making; 2009; 29(1):125-39. PubMed ID: 18566486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective.
    Wasserfallen JB; Krieg MA; Greiner RA; Lamy O
    J Med Econ; 2008; 11(3):499-523. PubMed ID: 19450101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.
    Rietbrock S; Olson M; van Staa TP
    QJM; 2009 Jan; 102(1):35-42. PubMed ID: 18842684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
    Emkey RD; Ettinger M
    Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the claim of enhanced persistence: the case of osteoporosis and implications for payers.
    Kelton CM; Pasquale MK
    Med Decis Making; 2009; 29(6):690-706. PubMed ID: 19542361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis.
    Cotté FE; Mercier F; De Pouvourville G
    Clin Ther; 2008 Dec; 30(12):2410-22. PubMed ID: 19167600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
    Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE
    Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low rates of treatment in postmenopausal women with a history of low trauma fractures: results of audit in a Fracture Liaison Service.
    Premaor MO; Pilbrow L; Tonkin C; Adams M; Parker RA; Compston J
    QJM; 2010 Jan; 103(1):33-40. PubMed ID: 19864348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recognition of women at risk for fracture and intervention with fast-acting therapies.
    Derman R
    Int J Fertil Womens Med; 2006; 51(4):183-90. PubMed ID: 17184104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential clinical and economic impact of nonadherence with osteoporosis medications.
    Hiligsmann M; Rabenda V; Gathon HJ; Ethgen O; Reginster JY
    Calcif Tissue Int; 2010 Mar; 86(3):202-10. PubMed ID: 20205345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of treatment benefit due to low compliance with bisphosphonate therapy.
    Penning-van Beest FJ; Erkens JA; Olson M; Herings RM
    Osteoporos Int; 2008 Apr; 19(4):511-7. PubMed ID: 17874028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
    Kanis JA; Johansson H; Oden A; McCloskey EV
    Bone; 2009 Jun; 44(6):1049-54. PubMed ID: 19254788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of treatment efficacy and dosing frequency on cost-effectiveness of bisphosphonate treatment for osteoporosis: a perspective.
    Boonen S
    Curr Med Res Opin; 2009 Oct; 25(10):2335-41. PubMed ID: 19650755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
    Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ
    Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [How to prevent early postmenopausal fracture risk? Proposition of a strategy].
    Trémollieres F; Pouilles JM; Ribot C
    Gynecol Obstet Fertil; 2009 Jan; 37(1):50-6. PubMed ID: 19110461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence to medical treatment of osteoporosis in women at three different clinical settings--a historical cohort study.
    Nielsen DS; Langdahl BL; Sørensen OH; Sørensen HA; Brixen KT
    Scand J Public Health; 2010 Jul; 38(5):502-7. PubMed ID: 20484306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Absolute risk for fracture and WHO guideline. Selection of drugs for the prevention of fractures in postmenopausal women].
    Gorai I;
    Clin Calcium; 2007 Jul; 17(7):1090-6. PubMed ID: 17607077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence.
    Rabenda V; Hiligsmann M; Reginster JY
    Expert Opin Pharmacother; 2009 Oct; 10(14):2303-15. PubMed ID: 19640210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simple computer model for calculating and reporting 5-year osteoporotic fracture risk in postmenopausal women.
    Ettinger B; Hillier TA; Pressman A; Che M; Hanley DA
    J Womens Health (Larchmt); 2005 Mar; 14(2):159-71. PubMed ID: 15775734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.